[P496] Examining the Effects of Pharmacological and Nutritional Interventions on Metabolic Syndrome Associated with Antipsychotic Treatment in Schizophrenia: A Systematic Review and Network Meta-analysis

*CHUN-I LIU¹, Yuan-Jen Tsai², Kah Kheng Goh^3,4 (1. Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan, 2. Department of Family Medicine, Taipei Medical University Hospital, Taipei, Taiwan, 3. Department of Psychiatry, Wan-Fang Hospital, Taipei Medical University, Taipei, Taiwan, 4. Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan)

[P497] Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) and SLE-related psychosis: Epidemiology, pathogenesis, treatments.

*KuoHeng Cheng¹, WenYu Hsu¹ (1. Changhua Christian Hospital)

[P499] A Naturalistic Retrospective Study of Aripiprazole Once-Monthly 400 mg Used for Schizophrenia

*Nan-Ying Chiu¹, Pei-Shan Kung¹ (1. Lukang Christian Hospital)

[P500] Evenamide as add-on treatment for patients with chronic schizophrenia not responding adequately to their current antipsychotic medication: results of a potentially pivotal, phase II/III, international, randomized, double blind, placebo-controlled trial

*Ravi Anand¹, Alessio Turolla², Giovanni Chinellato², Rodolfo Giuliani², Richard Hartman³ (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)

[P501] Remarkable efficacy of evenamide, a glutamate antagonist, as an add-on to antipsychotics in patients with treatment resistant schizophrenia (TRS): results from a one-year, open-label, dose-comparative, randomized, treatment trial

*Ravi Anand¹, Alessio Turolla², Giovanni Chinellato², Richard Hartman³ (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)

[P502] Evenamide, as an add-on to antipsychotics, produces long-lasting clinically meaningful benefit and converts treatment-resistant schizophrenia (TRS) patients into a responsive state: 6-month results from an ongoing international randomized study

*Ravi Anand¹, Alessio Turolla², Giovanni Chinellato², Francesca Sansi², Rodolfo Giuliani² (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA)

[P503] Evenamide as add-on treatment for treatment-resistant schizophrenia (TRS) patients not benefiting from antipsychotics: design of a phase 3, potentially pivotal, international, randomized, double-blind, placebo-controlled clinical trial

*Ravi Anand¹, Alessio Turolla², Giovanni Chinellato², Rodolfo Giuliani², Richard Hartman³ (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)

[P504] A retrospective comparative study of clinical response to clozapine between patients with early treatment-resistant schizophrenia (TRS) and late TRS

*Nobuhisa Kanahara^1,13, Kazuki Okada², Yuji Otsuka³, Remiko Kobayashi², Hiroshi Kimura⁴, Hiroshi Yamanaka⁵, Yuri Takaoki⁶, Taisuke Yoshida⁷, Takahiro Oiwa⁸, Fumiaki Ito⁹, Hiroshi Komatsu¹⁰, Takashi Ono¹¹, Yuki Kikuchi¹², Takahisa Saiga⁶, Shingo Noda¹³, Masaomi Iyo² (1. Chiba University Center for Forensic Mental Health, Chiba, Japan, 2. Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan, 3. Department of Psychiatry, Asahi General Hospital, Asahi, Japan, 4. Department of Psychiatry, Gakuji-kai Kimura Hospital, Chiba, Japan, 5. Department of Psychiatry, Chiba Psychiatric Medical Center, Chiba, Japan, 6. Department of Psychiatry, Japanese Red Cross Narita Hospital, Narita, Japan, 7. Department of Psychiatry, Doujin-kai Kisarazu Hospital, Kisarazu, Japan, 8. Department of Psychiatry, Naoki-kai Isogaya Hospital, Ichihara, Japan, 9. Department of Psychiatry, National Hospital Organization Hanamaki Hospital, Hanamaki, Japan, 10. Department of Psychiatry, Tohoku University Hospital, Sendai, Japan, 11. Department of Psychiatry, Miyagi Psychiatric Center, Natori, Japan, 12. Department of Psychiatry, Yukou-kai, Kodama Hospital, Ishinomaki, Japan, 13. Department of Psychiatry, Ichihara-Tsuruoka Hospital, Ichihara, Japan)

[P505] TARDIVE DYSKINESIA AS A SIDE EFFECT OF COMBINATION ADMINISTRATION OF HALOPERIDOL AND RISPERIDONE IN SCHIZOPHRENIC PATIENT WITH PASUNG: A CASE REPORT

*Ervana Ikha Yusnita¹, Bintang Arroyantri Prananjaya² (1. dr. H.M Rabain Muara Enim General Hospital, 2. Faculty of Medicine, Universitas Sriwijaya)

[P506] Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia

*Tianqi Gao¹, Chengcheng Pu¹, Haiyun Li², Xin Yu¹ (1. Peking University Sixth Hospital, Peking University Institute of Mental Health, 2. Medical Affairs, Sumitomo Pharma (Suzhou) Co., Ltd.)

[P507] The Efficacy of Metformin in Counteracting Olanzapine-Induced Hyperprolactinemia: An Open-Label Prospective Study

*Mong-Liang Lu^1,2,3, Kah Kheng Goh^1,2, Tzu-Hua Wu³, Chun-Hsin Chen^1,2 (1. Department of Psychiatry, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan, 2. Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, 3. Department of Clinical Pharmacy, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan)

[P508] Factors associated with the initiation of laxative use in the same patients with schizophrenia over a 20-year period: retrospective cohort study

*Yasushi Kawamata^1,2, Norio Sugawara^1,3, Taro Sasaki^1,4, Saaya Yokoyama^1,5, Hiroaki Okayasu^1,6, Masataka Shinozaki^1,7, Yoshitaka Takeuchi^1,8, Aoi Sato^1,9, Takaaki Ishikawa^1,10, Hazuki Komahashi-Sasaki^1,11, Kensuke Miyazaki¹², Takashi Fukasawa¹³, Hanako Furukori¹⁴, Norio Yasui-Furukori^1,3 (1. Department of Psychiatry, Dokkyo Medical University, School of Medicine, Tochigi, Japan, 2. Department of Psychiatry, Kikuchi Hospital, Tochigi, Japan, 3. Department of Psychiatry, TMC Shimotsuga, Tochigi, Japan, 4. Department of Psychiatry, Asahi Hospital, Tochigi, Japan, 5. Department of Psychiatry, Aoki Hospital, Tochigi, Japan, 6. Department of Psychiatry, Fudogaoka Hospital, Saitama, Japan, 7. Department of Psychiatry, Takizawa Hospital, Tochigi, Japan, 8. Department of Psychiatry, Okamotodai Hospital, Tochigi, Japan, 9. Department of Psychiatry, Muroi Hospital, Tochigi, Japan, 10. Department of Psychiatry, Saitama-Konan Hospital, Saitama, Japan, 11. Department of Psychiatry, Kanuma Hospital, Tochigi, Japan, 12. Department of Neuropsychiatry, Hirosaki-Aiseikai Hospital, Aomori, Japan, 13. Department of Psychiatry, Seinan Hospital, Aomori, Japan, 14. Department of Neuropsychiatry, Kuroishi-Akebono Hospital, Aomori, Japan)

[P509] Re-examination of psychiatric disorders from the viewpoint of antipsychotic-induced encephalopathy

*Satoshi A Hayama¹ (1. Faculty of Integrated Human Studies, Kyoto University, Kyoto, Japan)

[P510] The high rate of the adherence to pharmacotherapy guideline in recovery and remission in patients with schizophrenia: A cross-sectional study

*Ryo Asada¹, Hikaru Hori¹, Leo Gotoh¹, Kiyohiro Yasumatsu¹, Hitoshi Iida¹, Hiroaki Kawasaki¹ (1. Fukuoka University)

[P511] Efficacy of KarXT on Negative Symptoms in Acute Schizophrenia: An Analysis of Pooled Data from 3 Trials

*Scott Vuocolo¹, William P Horan¹, Amy Claxton ¹, Steven D Targum², Inder Kaul¹, Sharon Sawchak ¹, Andrew C Miller ¹, Steven M Paul¹, Stephen K Brannan ¹ (1. Karuna Therapeutics, Boston, MA, USA , 2. Signant Health, Boston, MA, USA)

[P513] Valuable Interaction with Cognitive Remediation and Optimal Antipsychotics for Recovery in Schizophrenia (VICTORY-S): Study Protocol for an Interventional, Open-Label, Rater-Blinded, Randomized Comparison of Combined Treatment with Cognitive Remediation and Lurasidone or Paliperidone

*Ryotaro Kubota¹, Satoru Ikezawa^1,2, Hideki Oi³, Mari S Oba³, Shoki Izumi³, Leona Adachi¹, Mako Miwa¹, Ryoko Tsuno¹, Shunji Toya⁴, Yohei Nishizato⁴, Daisuke Haga⁵, Tatsuro Iwane⁶, Kazuyuki Nakagome¹ (1. Department of Psychiatry, National Center of Neurology and Psychiatry Hospital, Tokyo, Japan, 2. Department of Psychiatry, International University of Health and Welfare Mita Hospital, Tokyo, Japan, 3. Clinical Research and Education Promotion Division, National Center of Neurology and Psychiatry, Tokyo, Japan, 4. CNS Group, Medical Science, Sumitomo Pharma Co., Ltd., Tokyo, Japan, 5. One More Job Training Institution, Toyonaka, Osaka, Japan, 6. Kyoto Prefectural Rakunan Hospital, Kyoto, Japan)

[P514] Relationships between schizophrenia severity and inflammatory biomarker: neutrophil/lymphocyte ratio, monocyte/lymphocyte ratio, platelet/lymphocyte ratio

*Ho Chan Kim¹, Seong Hwan Kim² (1. Department of Psychiatry, Kosin University Gospel Hospital, Busan, Republic of Korea, 2. Department of Psychiatry, Dong-A University Hospital, Busan, Republic of Korea)

[P515] Is there a difference in vestibular system reactivity between patients with schizophrenia and healthy control participants?

*Yasaman Kambari^1,2, Jianmeng Song^1,2, Aron Amaev^1,2, Ali Abdolizadeh^1,2, Edgardo Torres-Carmona^1,2, Fumihiko Ueno^1,2, Teruki Koizumi^1,2, John Rutka³, Emma LeBlanc³, Neil Bailie³, Wanda Dillon³, Kaitlin Harvey³, Laurel Palmer³, Ariel Graff-Guerrero^1,2, Philip Gerretsen^1,2 (1. Centre for Addiction and Mental Health (CAMH), Toronto, Ontario , 2. Institute of Medical Science, University of Toronto, Toronto, Ontario, 3. Toronto General Hospital, Toronto, Ontario)

[P517] The effect of food on the pharmacokinetics of a single oral dose of iclepertin (BI 425809), a glycine transporter 1 inhibitor, in healthy volunteers: A Phase I open-label, randomized, crossover trial

*Akiko Harada¹, Shilpa Madari², Arvid Jungnik³, Kerstin Breithaupt-Groegler³, Kathrin Hohl³ (1. Nippon Boehringer Ingelheim Co., Ltd, Hyogo, Japan , 2. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 3. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany)

Session information

Schizophrenia 5 - Clinical (3)